Details for Patent: 10,105,323

Which drugs does patent 10,105,323 protect, and when does it expire?

Patent 10,105,323 protects OFEV and is included in one NDA.

Protection for OFEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in thirty-four countries.

Summary for Patent: 10,105,323

Title:	Pharmaceutical dosage form for immediate release of an indolinone derivative
Abstract:	The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
Inventor(s):	Roman Messerschmid, Peter Lach, Torsten Sokoliess, Peter Stopfer, Dirk Trommeshauser
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US15/590,487
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,105,323
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,105,323

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	OFEV	nintedanib esylate	CAPSULE;ORAL	205832-001	Oct 15, 2014	AB	RX	Yes	No	10,105,323*PED				Y
Boehringer Ingelheim	OFEV	nintedanib esylate	CAPSULE;ORAL	205832-002	Oct 15, 2014	AB	RX	Yes	Yes	10,105,323*PED				Y

Foreign Priority and PCT Information for Patent: 10,105,323

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08157750	Jun 6, 2008

International Family Members for US Patent 10,105,323

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072060
Australia	2009254556
Brazil	PI0913235
Canada	2726648